M. Pettilä and M. Varpula, Oulu: T Ala-Kokko; France: CHRU de Tours Hopital Bretonneau, Tours: D Perrotin; CHRU de Limoges Hopital Dupuytren Hospital Les Oudairies Angouleme Hospital

R. Spain-artigas and . Ferrer, Birmingham Heartlands Hospital, Birmingham: G Raghuraman; Guy's and St. Thomas's NHS Foundation Trust: S Drage; Imperial College Healthcare NHS Trust, D Wyncoll; Royal Berkshire Hospital, Reading: A Kapila; Queen Elizabeth Hospital Norfolk: M Blunt; Royal Sussex Country Hospital

. Joseph-'s, M. Hospital, . Center, . Phoenix, . Siever et al., Louis: R Lakshmanan; Moses Cone Hospital, Greensboro: P Wright; University of California San Francisco at Fresno, Fresno: K Van Gundy; Rapid City Regional Hospital, Rapid City: J Reyno; Veterans Affairs Medical Center Houston, M Saad. Author details 1

W. Street, N. Washington, and D. , Eli Lilly and Company, Lilly Corporate Centre, 893 South Delaware Street, Critical Care Center, vol.110, issue.3 4, p.8208, 20010.

R. Dellinger, S. Townsend, W. Linde-zwirble, J. Marshall, J. Bion et al., Surviving Sepsis Campaign, Critical Care Medicine, vol.41, issue.2, pp.367-374, 2010.
DOI : 10.1097/CCM.0b013e31827e83af

S. Sheth and A. Carvalho, Protein S and C alterations in acutely III patients, American Journal of Hematology, vol.4, issue.1, pp.14-19, 1991.
DOI : 10.1002/ajh.2830360104

G. Bernard, J. Vincent, P. Laterre, S. Larosa, J. Dhainaut et al., Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis, New England Journal of Medicine, vol.344, issue.10, pp.699-709, 2001.
DOI : 10.1056/NEJM200103083441001

S. Yan, J. Helterbrand, D. Hartman, T. Wright, and G. Bernard, Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis, Chest, vol.120, issue.3, pp.915-922, 2001.
DOI : 10.1378/chest.120.3.915

G. Kinasewitz, S. Yan, B. Basson, P. Comp, J. Russell et al., Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism, Critical Care, vol.8, issue.2, pp.82-90, 2004.
DOI : 10.1186/cc2459

F. Fourrier, C. Chopin, J. Goudemand, S. Hendrycx, C. Caron et al., Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation, Chest, vol.101, issue.3, pp.816-823, 1992.
DOI : 10.1378/chest.101.3.816

J. Lorente, L. García-frade, L. Landín, R. De-pablo, C. Torrado et al., Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome, Chest, vol.103, issue.5, pp.1536-1542, 1993.
DOI : 10.1378/chest.103.5.1536

R. Mesters, J. Helterbrand, B. Utterback, S. Yan, Y. Chao et al., Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications, Critical Care Medicine, vol.28, issue.7, pp.2209-2216, 2000.
DOI : 10.1097/00003246-200007000-00005

. Shorr, Critical Care, p.229, 2010.

A. Shorr, D. Nelson, D. Wyncoll, K. Reinhart, F. Brunkhorst et al., Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated), Critical Care, vol.12, issue.2, p.45, 2008.
DOI : 10.1186/cc6854

W. Macias and D. Nelson, Severe protein C deficiency predicts early death in severe sepsis, Critical Care Medicine, vol.32, issue.Supplement, pp.223-228, 2004.
DOI : 10.1097/01.CCM.0000126120.49367.AC

A. Shorr, G. Bernard, J. Dhainaut, J. Russell, W. Macias et al., Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome, Critical Care, vol.10, issue.3, p.92, 2006.
DOI : 10.1186/cc4946

F. Brunkhorst, Y. Sakr, S. Hagel, and K. Reinhart, Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis, Anesthesiology, vol.107, issue.1, pp.15-23, 2007.
DOI : 10.1097/01.anes.0000267531.39410.d3

J. Dhainaut, P. Laterre, J. Janes, G. Bernard, A. Artigas et al., Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial, Intensive Care Medicine, vol.1, issue.6, pp.894-903, 2003.
DOI : 10.1007/s00134-003-1731-1

R. Vangerow, A. Shorr, D. Wyncoll, J. Janes, D. Nelson et al., The protein C pathway: implications for the design of the RESPOND study, Critical Care, vol.11, issue.Suppl 5, p.4, 2007.
DOI : 10.1186/cc6155

K. Lui and M. Matthay, Protein C as a surrogate end-point for clinical trials of sepsis, Crit Care, vol.12, p.139, 2008.

E. Rivers, J. Kruse, G. Jacobsen, K. Shah, M. Loomba et al., The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock*, Critical Care Medicine, vol.35, issue.9, pp.2016-2024, 2007.
DOI : 10.1097/01.CCM.0000281637.08984.6E

J. Vincent, G. Bernard, R. Beale, C. Doig, C. Putensen et al., Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*, Critical Care Medicine, vol.33, issue.10, pp.2266-2277, 2005.
DOI : 10.1097/01.CCM.0000181729.46010.83

D. Ahishakiye, S. Lorent, D. Backer, D. Gottignies, P. Vincent et al., Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?, Journal of Critical Care, vol.24, issue.4, pp.590-594, 2009.
DOI : 10.1016/j.jcrc.2009.03.009

T. Dravid, B. Pawar, B. Bhurke, P. Akole, P. Rajhans et al., Activated protein C: cost matters! Crit Care, p.405, 2010.

M. Hochreiter, T. Köhler, A. Schweiger, F. Keck, B. Bein et al., Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial, Critical Care, vol.13, issue.3, p.83, 2009.
DOI : 10.1186/cc7903